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Basic Investigation 
Dangfei Liganning Capsules (ᔧ亲߽㙱ᅕ㛊ಞ) Attenuate the 
Susceptibility of Rat Nonalcoholic Fatty Liver to Carbon Tetrachloride 
Toxicity  
SONG Hai-yan ᅟ⍋➩ 1,2, MAO Zhi-min ↯ᖫᬣ 1,2, YANG Li-li ᴼББ 1,2, LIU Tao ᷇⍯ 1,2,  
LI Dong-fei ࢅހ᭤ 1,2, ZHANG Li ᓴ㥝 1,2, GE Ying-li 㨯䖢߽ 1,2, ZHENG Pei-yong 䚥෍∌ 1,2,  
LIU Ping ߬ᑇ 3, ZHANG Xiao-qi ᓴᄱ唤 4, and JI Guang ᄷܝ 1,2,3
Objective: To test whether nonalcoholic hepatic steatosis sensitizes carbon tetrachloride (CCl4)–induced liver injury, 
and to assess the therapeutic effect of Chinese medicine extracts of Dangfei Liganning capsules (ᔧ亲߽㙱ᅕ㛊ಞ) 
and their potential underlying mechanisms.  
Methods: Male Wistar rats were fed a high-fat diet to induce nonalcoholic fatty liver disease (NAFLD) or a normal 
diet (N). Eight weeks later, a nonlethal dose of CCl4 was applied intraperitoneally. From the start, HF-CCl4 rats 
were administered daily Dangyao extracts (D), Dangfei Liganning capsules (DF), or Diammonium Glycyrrhizinate 
(G) intragastrically. Rats were sacrificed 48 h after CCl4 administration. In addition to serum biochemistry, liver 
histopathology was observed using hematoxylin-eosin (HE) and oil red O staining, and hepatic levels of triglyceride 
(TG), malondialdehyde (MDA), glutathione (GSH), superoxide dismutase (SOD), caspase-3 activation and 
cytochrome P450 (CYP2E1) expression were assessed. 
Results: There was almost no response to the nonlethal dose of CCl4 in the N control group. However, the HF 
group demonstrated massive steatosis, and elevated levels of serum ALT and AST, liver MDA, CYP2E1, and 
caspase-3 activation, whereas the levels of GSH and SOD were significantly decreased. All indexes assessed were 
dramatically worse in the HF-CCl4 group compared to the HF group, in addition to the more severe steatosis, 
hepatocyte ballooning, and inflammatory infiltration apparent in the centrilobular area. The medicines we tested 
affected the pathological changes in HF-CCl4 rats to differing degrees: DF and G led to improvements in all of the 
above examined indexes, including an obvious improvement in histopathology, and DF improved serum ALT and 
MDA levels more markedly than G, whereas D extracts produced only mild liver injury attenuation. 
Conclusion: Liver with NAFLD is more sensitive to hepatotoxicity; furthermore, the disrupted balance of oxidative 
stress and anti-oxidant defense contributes to the underlying mechanisms. Dangfei Liganning capsules potentially 
decrease this toxic susceptibility and alleviate liver injury in non-alcoholic fatty liver. 
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Nonalcoholic fatty liver disease (NAFLD) refers to a 
wide spectrum of liver damage that ranges from simple 
steatosis to nonalcoholic steatohepatitis (NASH), 
advanced fibrosis, and cirrhosis.1,2 It is the most common 
chronic liver disease and is a major cause of elevation of 
liver enzymes worldwide. Currently, the prevalence is 
estimated to be 20%–30% in Western countries, 
12%–15% in Asian countries, and it is rapidly increasing 
in parallel with the upward trends in obesity and type 2 
Diabetes.3,4 The “2 hit” hypothesis proposed in 1998 is 
widely accepted to explain the pathogenesis in which 
insulin resistance and oxidative stress are key factors in 
NAFLD development.5
Simple nonalcoholic fatty liver (NAFL) is usually 
ignored and not considered to be a disease because 
affected patients do not present with identifiable signs 
and symptoms or recognizable etiological agents. 
However, previous experiments have demonstrated that 
enhanced liver sensitivity to acute toxic injury in 
NAFLD,6,7 leads to severe liver dysfunction.  A clinical 
investigation demonstrated that NAFLD patients were 
more susceptible to acute hepatotoxicity due to 
pharmacological agents taken for other illnesses and that 
presence of NAFLD was an independent risk factor in 
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determining drug-related acute hepatitis, with an odds 
ratio of 3.95.8 Therefore, elucidation of the underlying 
mechanisms of this increased toxic sensitivity of NAFLD 
liver is warranted in order to develop novel therapies to 
prevent development of severe liver disease. Dangfei 
Liganning capsules (DF ᔧ亲߽㙱ᅕ㛊ಞ) contain a 
mixture of alcohol extracts from the Chinese traditional 
herbal medicines Dangyao (Herba Swertiae) and 
Shuifeiji (Fructus Silybi). These capsules have been 
applied in a clinical setting to protect liver function in 
various liver diseases and have been demonstrated to 
lessen liver damage induced by drugs for tuberculosis.9-13
The purpose of this study is to initially determine 
whether NAFLD sensitizes the liver to hepatotoxicity 
and to investigate the underlying mechanisms, as well as 
to investigate whether Dangfei Liganning capsules could 
attenuate susceptibility and protect the liver from heavy 
injury and determine the underlying mechanisms 
involved. 
MATERIALS AND METHODS 
Drugs and Reagents 
DF was provided by Sichuan Medco Pharmaceutical 
Company (ಯᎱ㕢໻ᒋ㥃Ϯ᳝䰤݀ৌ, Shifang, Sichuan, 
China); the compound in the capsules is a mixture of 
alcohol extracts from Dangyao (Herba Swertiae) and 
Shuifeiji (Fructus Silybi). Dangyao extract (D) was also 
provided by this company. Diammonium Glycyrrhizinate 
Enteric-coated capsules (G, ⫬㤝䝌Ѡ䫉㙴⒊㛊ಞ) are 
the product of Chia Tai Tianqing Pharmaceutical 
Company (ℷ໻໽᱈㥃Ϯ㙵ӑ᳝䰤݀ৌ, Lianyungang, 
Jiangsu, China). The dose used for rats was seven times 
that of a human adult.  
Mouse monoclonal anti-CYP2E1 and rabbit polyclonal 
anti-UCP2 were the products of Abcam Inc., mouse 
monoclonal anti-cleaved caspase-3 was purchased from 
Cell Signaling Technology, Inc., and PVDF membrane 
and ECL reagents were from Millipore Corporation. 
Chemistry reagents were purchased from Sigma Aldrich 
Company or Sinopharm Chemical Reagent Company.  
Animals and Experimental Design 
Seventy male Wistar rats were purchased from Slac 
Laboratory Animal Company, with initial weight of 170± 
10 g. The rats were housed at 24±2 °C, 55±10% 
humidity with a 12-hour photoperiod. Rats were fed with 
high-fat diet (HF, 88% normal chow + 10% lard + 2% 
cholesterol) or a standard normal diet (N) for 8 weeks. 
Next, 33% CCl4 (1:2 dissolved in corn oil for injections, 
0.5 mL / 100 g body weight) was applied 
intraperitoneally. From the initiation of this experiment, 
some of the HF-CCl4 rats were administrated 
intragastrically each day with Dangyao extract D, DF, or 
G, respectively. Animals were sacrificed 48 h following 
CCl4 administration, and liver and serum samples were 
obtained and immediately frozen in liquid nitrogen, then 
stored at -80 °C until analysis. 
Measurement of Serum Biochemistry  
Serum was separated via centrifugation, and activity 
levels of alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) were measured using HITACHI 
7170S biochemistry analysis equipment. 
Liver Histopathology Assessment 
Similar portions of liver tissue were fixed by immersion 
in 10% neutral formaldehyde for 24 h. Four ȝm slices of 
paraffin-embedded sections were routinely processed for 
hematoxylin-eosin (HE) staining. Frozen sections fixed 
in 4% neutral paraformaldehyde were stained with oil 
red O and utilized to confirm liver steatosis. Liver 
histology was examined under a light microscope. 
Measurement of Liver Tissue Triglyceride 
A total of 200 mg of liver tissue was minced and added 
to a mixture of alcohol and acetone for homogenization; 
samples were then centrifuged at 10,000 rpm/min for 20 
s and stored overnight at 4 °C. After centrifugation, 
sample supernatants were collected and analyzed for 
hepatic triglyceride content in accordance with the kit 
manual instructions from Nanjing Jiancheng Bioengineer 
Institute.  
Determination of Liver Malondialdehyde, 
Glutathione and Superoxide Dismutase  
Samples of 10% liver homogenate (500 mg liver tissues 
in 4.5 mL 0.9% NaCl) were prepared, and protein 
concentrations were examined using the Bradford 
method. Hepatic malondialdehyde (MDA) and reduced 
Glutathione in the homogenate were measured using 
colorimetric microplate assays in accordance with the kit 
manual instructions of Beyotime Institute of 
Biotechnology. Liver SOD was determined using the 
SOD assay kit from Dojindo Laboratories. The assay kit 
measured the mitochondrial activity via production of a 
water-soluble formazan dye upon reduction with 
superoxide anion; the rate of this reduction was linearly 
correlated to xanthine oxidase (XO) activity and was 
inhibited by SOD. Thus, the rate of XO inhibition as 
determined by a colorimetric method was used to reflect 
the serum SOD levels in this study. 
Western Blot Analysis of Hepatic CYP2E1 Expression 
and Caspase-3 Activation  
Liver tissues were homogenized in RIPA buffer and 
protein concentrations were determined using the BCA 
method. The whole liver protein extracts were resolved 
by SDS-PAGE gel electrophoresis and transferred to a 
PVDF membrane. After blocking, immunoblotting was 
performed for each primary antibody against CYP2E1 
(1:1000), cleaved caspase-3 (1:500), and GAPDH 
(1:1000) as internal loading control, then incubated with 
the secondary antibodies against rabbit or mouse. The 
blots were developed using the ECL western blotting 
system and analyzed by computerized densitometry 
(Tanon, Labworks 4.6 software). 
Statistical Analysis 
Data were expressed as the mean ± standard deviation 
(SD). Comparisons were made among the groups using 
one-way ANOVA, followed by Tukey-Kramer’s post test 
to assess the specific pairs of groups using Graph-Pad 
Prism5 and SPSS16.0 software. A P value of less than 
Journal of Traditional Chinese Medicine, December 2011; 31(4): 327-333 329
0.05 was considered to represent a statistically 
significant result.  
RESULTS 
Histopathology 
According to liver tissue HE staining results (Figure 1), 
rats fed a HF diet exhibited massive steatosis in liver 
tissue, with abundant accumulation of fat droplets in 
hepatocytes, whereas the liver tissues from rats fed a 
normal diet exhibited no signs of steatosis. There was 
almost no pathologic change in the N-CCl4 group aside 
from very mild steatosis that was observed in some 
samples. In contrast, liver damage was more severe in 
the HF-CCl4 group compared to the HF group: in 
addition to the more diffuse hepatosteatosis observed, 
there was evidence of infiltration of a mixed population 
of inflammatory cells in the centrilobular regions, as well 
as numerous areas of ballooning hepatocyte degeneration 
characterized by cell swelling, rarefied cytoplasmic 
content, Mallory-Denk bodies, and small apoptotic 
bodies. DF and G intervention markedly protected the 
liver from histopathological injuries, including almost no 
inflammatory infiltration and a decrease in the degree of 
hepatosteatosis. D also lessened the degree of hepatitis, 
although it functioned less effectively than DF and G. 
Liver tissue samples stained with oil red O (figure is not 
shown) also confirmed the hepatosteatosis results seen in 
the HF group which was more diffuse in the HF-CCl4 
group and was alleviated by DF and G treatment.  
Figure 1. Histopathology of liver tissues from rats of groups: N (A), N-CCl4 (B), HF (C), HF-CCl4 (D), D (E), DF (F) or 
G (G). Sections were stained with HE, original magnification is 200×. CV represents centrilobular vein. Black arrow 
indicates hepatocyte ballooning degeneration with Mallory–Denk body, arrow head shows a hepatic apoptotic body, and 
white arrow shows infiltration of inflammatory cells.
Serum Aminotransferase 
Compared with N, the serum ALT or AST levels were 
elevated in the HF group (P<0.01). The two 
aminotransferases between N and N-CCl4 exhibited 
almost no difference, whereas there were significant 
changes between HF and HF-CCl4 (P<0.01). In 
comparison with HF-CCl4, both aminotransferases were 
dramatically decreased in the DF and G groups (P<0.01), 
whereas only AST was reduced in the D group (P<0.01). 
The ALT level of the DF group was even lower than the 
HF group without toxic stimulation (P<0.05). (Data 
shown in Table 1 and Figure 2).  
Table 1. Serum ALT and AST in the Groups ( xfƐ, n=10)
Group ALT (U/L) AST (U/L) 
N  32.92±4.17**##    41.79±7.16**##
N-CCl4  39.84±4.43**##  50.17±1.61** 
HF  57.33±10.01**   65.18±19.43** 
HF-CCl4 82.90±15.80## 84.14±7.90##
D 71.71±6.68#    45.32±11.73**##
DF 43.28±3.63**#    38.42±13.35**##
G 49.64±12.84**   31.97±7.27**##
Notes: Compared with HF-CCl4 group, *P<0.05, **P<0.01; compared with HF group, #P<0.05, ##P<0.01. 
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Figure 2. Serum activity of ALT (A) and AST (B). The values represent the mean ± SD. *P<0.05, **P<0.01 compared to 
HF-CCl4 group; #P<0.05, ##P<0.01 compared to HF group. 
Liver Triglyceride, Malondialdehyde, Glutathione, 
and Superoxide Dismutase
The triglyceride (TG) content mirrored the degree of 
hepatic steatosis, and the HF diet appeared to induce 
dramatically greater TG accumulation in the liver 
compared to the N diet (P<0.01). The TG level exhibited 
almost no change between N and N-CCl4, whereas 
between HF and HF-CCl4 there was a significant 
difference (P<0.01). Treatment with DF or G reduced the 
TG level efficiently with HF-CCl4 or HF equally 
(P<0.01), so did D (P<0.01 vs HF-CCl4, P<0.05 vs HF). 
(Data shown in table 2 and figure 3A). 
Compared with N, MDA and SOD increased, whereas 
GSH decreased significantly in the HF group (P<0.01). 
No changes were observed in these indexes between N 
and the N-CCl4 group, but MDA was elevated and GSH 
markedly reduced in the HF-CCl4 group compared to the 
HF group (P<0.01), and the SOD activity exhibited a 
decreasing trend. Treatment by DF, G (P<0.01) and D 
(P<0.05) reduced the MDA level, and DF and G 
significantly reverted the reduced GSH and SOD levels 
(P<0.01), whereas D only exhibited a slight effect. (Data 
shown in table 2 and figure 3B, C, D). 
Hepatic CYP2E1 Protein Expression and Caspase-3 
Activation Level 
Western blot analyses of liver CYP450 isoform 2E1 and 
cleaved caspase-3 protein expression are shown in figure 
4. First, compared with N, a HF diet induced an increase 
in CYP2E1 expression and caspase-3 activation (P<0.01). 
No differences were observed between N and N-CCl4, 
whereas marked increases were shown in HF-CCl4
compared to HF (P<0.01). Treatment with DF and G 
reverted both the elevated CYP2E1 and cleaved 
caspase-3 expression levels significantly (P<0.01), 
whereas D reduced CYP2E1 expression levels (P<0.01). 
(Data shown in Figure 4). 
Table 2. Liver TG, MDA, SOD and GSH ( xfs, n=10)
Group TG 
(mg/g liver) 
MDA 
(ȝmol/g protein) 
GSH 
(mg/g protein) 
SOD 
(inhibition%) 
N  0.77±0.26**##    5.30±1.17**## 106.57±10.62**##    0.36±0.06**##
N-CCl4  0.93±0.12**##    5.55±0.89**## 104.15±11.32**##    0.34±0.04**##
HF 1.73±0.16**   8.05±1.53** 71.59±13.54** 0.25±0.04 
HF-CCl4 2.11±0.12## 10.11±1.13## 28.10±9.07## 0.20±0.04 
D 1.45±0.28**#  8.35±1.51* 32.77±14.02## 0.23±0.06 
DF  1.20±0.12**##   6.50±0.67**  51.48±17.21**#   0.29±0.04** 
G  1.18±0.13**##   7.58±0.64**  51.96±15.77**#   0.31±0.02** 
Notes: Compared with HF-CCl4 group, *P<0.05, **P<0.01; compared with HF group, #P<0.05, ##P<0.01. 
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Figure 3. Liver Triglyceride (A), Malondialdehyde (B), Glutathione (C), and Superoxide Dismutase (D) of the Groups. 
The values represent mean ± SD.*P<0.05, **P<0.01 compared to HF-CCl4 group; #P<0.05, ##P<0.01 compared to HF 
group. 
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Figure 4. Immunoblot analysis of liver CYP2E1 protein expression and caspase-3 activation level, with GAPDH as the 
internal loading control. A representative blot from 3 replicates (n=3) is shown (A). Densitometric analysis of CYP2E1 
protein normalized to GAPDH (B). Densitometric analysis of cleaved caspase-3 normalized to GAPDH (C). The values 
represent mean ± SD. *P<0.05, **P<0.01 compared to HF-CCl4 group; #P<0.05, ##P<0.01 compared to HF group. 
Journal of Traditional Chinese Medicine, December 2011; 31(4): 327-333 

332
DISCUSSION 
Although high fat diet (HFD) induced NAFLD animal 
models require a lengthy feeding period, these models 
resemble the pathophysiology observed in human 
NAFLD closely, including induced obesity, insulin 
resistance, and hepatic steatosis in mice or rats14,15. In 
this study, serum ALT, AST, and liver TG levels are
elevated in rats of the HF group, and histopathology 
demonstrated marked diffuse fatty droplet accumulation 
which was used as the hepatotoxin to study the 
mechanisms of liver injury.4,16 We determined the 
appropriate dosage of CCl4 that led to almost no 
observed changes in normal rats and obvious liver 
damage in NAFLD rats. Livers of HF rats exhibited 
more significant diffuse steatosis 48 h after CCl4 was 
applied intraperitoneally, and infiltration of inflammatory 
cells and ballooning degeneration in the centrilobular 
region was apparent. Hepatocellular ballooning is an 
important histological parameter in the diagnosis of 
nonalcoholic steatohepatitis (NASH), indicating a greater 
risk of disease progression.17,18 In addition, elevated 
levels of aminotransferases were indicative of the liver 
injury and severe liver dysfunction caused by CCl4. The 
results suggested that liver tissue affected with NAFLD 
is more susceptible to hepatotoxin; thus, nonlethal doses 
of toxins/drugs for healthy people could potentially cause 
severe liver damage in NAFLD patients, and attention to 
this in a clinical setting is warranted. 
Oxidative stress (OS) caused by reactive oxygen species 
(ROS) is involved in the mechanism of variant liver 
injury, including damage due to hepatotoxin and 
NAFLD.19,20 OS is one of the second hits, believed to be 
of major importance in mediating the progression of 
NAFLD to NASH.5,21 In simple hepatosteatosis, the 
hepatic anti-oxidant defense system is regulated to keep 
the balance with pro-oxidant factors. When the amount 
of ROS overwhelms the adaptive buffering capacity, 
DNA mutations, peroxidation of membranes, stellate cell 
activation, inflammation, apoptosis, and generation of 
additional free radicals may occur, leading to hepatic 
injury.22,23 MDA is one of the major aldehydic 
metabolites of lipid peroxidation and is widely utilized to 
reflect lipid peroxidation and oxidative stress level. SOD 
is a key anti-oxidative enzyme, and reduced GSH may 
reflect the anti-oxidative status. In our study, HF rats 
demonstrated a higher level of lipid peroxidation MDA 
compared with N rats, and lower levels of anti-oxidants 
reduced GSH and SOD activity. However, no apparent 
hepatocyte degeneration or apoptosis was observed, 
which suggests that the liver tissue of the HF group was 
adaptive of OS. No pathologic change occurs in normal 
liver tissue due to low dosage of CCl4 because of the 
liver function of detoxication.24 However, in NAFLD 
liver detoxification is associated with activated enzymes 
or molecules that may be almost exhausted; thus, CCl4 
may be transformed, leading to the generation of more 
ROS and liver injury. Therefore, the livers of HF-CCl4 
rats demonstrated an even higher content of MDA and 
lower level of GSH and SOD, with the appearance of 
dramatic hepatocyte ballooning degeneration and 
apoptotic bodies, as well as increased cleaved caspase-3 
levels. CYP450 isoform 2E1 has been shown to be one 
of the most potent microsome cytochromes to generate 
ROS. Liver CYP2E1 is accepted as the hallmark of 
oxidative stress. In previous studies it has been shown to 
be invariably elevated in the livers of NASH patients.25
In this study, we also observed elevated CYP2E1 
expression in HF group and an even higher level in 
HF-CCl4 group.  
To prevent or relieve severe liver injury caused by 
hepatotoxin in NAFLD patients, appropriate intervention 
should be taken to reduce hepatotoxic susceptibility. 
Herein, we studied the effect of liver-protective medicine 
Dangfei Liganning capsules and one of its components, 
Dangyao extract, as well as Diammonium 
Glycyrrhizinate as the positive therapeutic control. Our 
results demonstrated that, DF and G treatment of 
HF-CCl4 rats significantly improved liver function by 
decreasing the serum ALT and AST level, reducing liver 
TG accumulation, and lowering caspase-3 activation; the 
histopathology results exhibited less inflammation and 
loss of ballooning degeneration and apoptosis. This 
effect may be correlated with an adjustment of OS 
associated factors, as MDA content and CYP2E1 
expression were markedly reduced, whereas GSH and 
SOD were elevated in the DF and G groups. D also 
exhibited a protective effect, however, it appeared to 
have a less efficient influence in reversing ALT, GSH and 
SOD levels; thus, in the livers of the D group ballooning 
hepatocytes still could be observed in proximity to the 
central vein. In addition, when compared with HF group, 
we demonstrated that DF also improved the pathogenic 
factors of NAFLD, including serum ALT, AST, liver TG, 
MDA, GSH, and CYP2E1 levels; moreover, the HE and 
oil red O staining results of the liver sections 
demonstrated fewer fatty droplets. These results suggest 
that DF not only extenuated the sensitivity of NAFLD to 
hepatotoxicity, but also improved the hepatosteatosis of 
NAFLD. 
In summary, this study demonstrated that hepatosteatosis 
induced by a high fat diet significantly sensitizes liver 
tissue to hepatotoxic injury. One of the major underlying 
causes is the disrupted balance between pro-oxidants and 
anti-oxidants during NAFLD development as well as 
hepatotoxicity stimulation. Our findings also indicated 
that Dangfei Liganning capsules could attenuate this 
sensitivity and protect fatty liver tissue effectively from 
severe liver dysfunction, and that regulation for oxidative 
stress associated factors contributes to the therapeutic 
mechanism. 
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